IVA - Inventiva S.A.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.0000 (0.00%)
At close: 04:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close2.8200
Bid2.7100 x 900
Ask2.8500 x 3000
Day's Range2.7431 - 2.9700
52 Week Range2.2200 - 11.7500
Avg. Volume19,783
Market Cap116.422M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Insider Monkey

    Inventiva S.A. (NASDAQ:IVA) Q4 2022 Earnings Call Transcript

    Inventiva S.A. (NASDAQ:IVA) Q4 2022 Earnings Call Transcript March 30, 2023 Operator: Good day and thank you for standing by. Welcome to the Inventiva 2022 Full Year Results Call and Webcast. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please note that today’s conference […]

  • Benzinga

    Inventiva To Change Clinical Development of Its Lead NASH Candidate

    Inventiva (NASDAQ: IVA) has decided to modify the clinical development plan of lanifibranor for non-alcoholic steatohepatitis (NASH). The changes follow a consultation with the FDA, Inventiva said.* Inventiva had initially designed a two-part study where part one would support accelerated approval with data from 900 patients, and part two would follow 2,000 patients for up to seven years. The company is now replacing part 2 with a new, separate Phase 3 trial that will enroll around 800 patients

  • Zacks

    Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus

    Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

  • Benzinga

    After 10 Years Of Collaboration, AbbVie Discontinues Inventiva-Partnered Psoriasis Candidate

    Inventiva (NASDAQ: IVA) said that AbbVie Inc (NYSE: ABBV) would stop developing cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study. Inventiva's cash runway, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility, is not impacted by the discontinuation of the cedirogant clinical program and

  • Benzinga

    Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst

    Last week, Inventiva (NASDAQ: IVA) announced a licensing and collaboration agreement with Sino Biopharm's subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to develop and commercialize lanifibranor in Greater China. Regardless of CTTQ's decision on lanifibranor's clinical development pathway in China, HC Wainwright notes that Sino Biopharm is a vertically-integrated company with substantial R&D, manufacturing, sales, and marketing capability. The analyst regards the collaboration as a fin

  • Benzinga

    Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

    Inventiva (NASDAQ: IVA) and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan. Inventiva will receive an upfront payment of $12 million, and $5 million are also expected in the short term if certain clinical milestones are met. Inventiva has the

  • Zacks

    Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks

    Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  • Zacks

    Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher

    Inventiva S.A. Sponsored ADR (IVA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.